| The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor‘s conference coverage. |
Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) significantly improved progression-free survival (PFS) and overall survival (OS) among patients with resectable gastric cancers compared with epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX), according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.1
Professor Salah-Eddin Al-Batran of the Institute of Clinical Oncology Research in Germany presented the data.
Continue Reading
FLOT4 is a phase 3, randomized trial (ClinicalTrials.gov Identifier: NCT01216644) conducted for patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinomas. Patients were randomly assigned to FLOT or to ECF/ECX, which are the standard of care.
Of 716 patients enrolled, 360 patients received ECF/ECX and 356 patients received FLOT. Baseline characteristics across the 2 arms were similar with respect to gender, age, disease stage, and type of cancer.
In the ECF/ECX arm, 91% and 37% of patients completed the planned preoperative and postoperative treatments. Correspondingly, in the FLOT arm, 90% and 50% of patients completed the planned preoperative and postoperative treatments.
After a median follow up of 43 months, median OS was 35 months with ECF/ECX and 50 months with FLOT (hazard ratio, 0.77; P = .012). Three-year OS was 48% for ECF/ECX and 57% for FLOT.
FLOT also significantly improved PFS, with a median of 30 months with FLOT and 18 months with ECF/ECX.
Perioperative complications were similar across the 2 arms: 50% with ECF/ECX and 51% with FLOT. More cases of grade 3 to 4 nausea and vomiting were seen with ECF/ECX and more cases of grade 3 to 4 neutropenia were seen with FLOT.
RELATED: Pembrolizumab Active in Advanced Gastric Cancer
“FLOT is the new standard of care in perioperative treatment of patients with adenocarcinomas of the stomach or gastroesophageal junction,” Prof Al-Batran concluded.
Read more of Cancer Therapy Advisor‘s coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.
Reference
- Al-Batran SE, Homann N, Schmalemberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(suppl; abstr 4004).
